News
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
1d
Money Talks News on MSNAre Your Weight-Loss Drugs Real? Novo Nordisk Sounds Alarm on KnockoffsOne in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...
Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
In a video shared to TikTok via her page, @lucy52915, which has racked up more than 750,000 views, she revealed pictures of ...
1d
GlobalData on MSNFangzhou and Novo Nordisk link on chronic disease managementThe joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...
Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...
Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results